

Invega Sustenna® Review

1. You are preparing to administer Invega Sustenna® to a patient who weighs 146 pounds. What size needle will you use? 1 inch, 23-gauge needle
2. Name the most common side effects a patient may experience when taking Invega Sustenna®.
Injection site reaction, sleepiness, dizziness, feeling restlessness, abnormal muscle movement including tremors, shuffling, uncontrolled involuntary movements, and abnormal movements of your eyes
3. What black box warning is associated with this medication? Increased mortality in elderly patients with dementia related psychosis
4. What are the standard *recommended* Day 1 and Day 8 initiation dosages for a person with schizophrenia? Day 1 is 234mg- Day 8 is 156 mg
5. What is the standard *recommended* maintenance dosage for a patient with schizophrenia? 117mg
6. What is the correct location for administration of the Day 1 and Day 8 initiation doses? Deltoid
7. What are the *recommended* Day 1 and Day 8 initiation dosages for a person with a creatinine clearance of 65mL/min? Day 1 is 156mg and day 8 is 117mg

8. What would the *recommended* maintenance dosage be for a patient with mild renal impairment? 78mg
9. What is the rationale for a trial of oral paliperidone or oral or injectable risperidone before placing a patient on Invega Sustenna®? To establish tolerability
10. Name three practices when preparing an intramuscular injection that ensure aseptic technique is maintained throughout the procedure. Perform proper hand hygiene, maintain a clean work area, use new and sterile equipment and clean needle
11. Explain the rationale for obtaining consent for this psychoactive medication prior to preparing the medication for administration.
Primarily based on respecting patient autonomy, recognize the higher risk associated with these medications, and fostering a collaborative, trusting relationship between the patient and provider. Right to refuse